The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation
Frontiers in Immunology, 15 November 2022 - www.frontiersin.org

Harmine is a dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor that displays a number of biological and pharmacological properties. Also referred to as ACB1801 molecule, we have previously reported that harmine increases the presentation of major histocompatibility complex (MHC)-I-dependent antigen on melanoma cells. Here, we show that ACB1801 upregulates the mRNA expression of...

Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?

Cancers, 03 March 2022

MHC-1 Mediated Antigen Presentation Machinery as a Key of Tumor Cells Immune Escape Control

Journal of immunology sciences, 08 February 2021

The "Holy Grail" in Immuno-Oncology : AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Chimia, October 2020

The β-carboline Harmine Induces Actin Dynamic Remodeling and Abrogates the Malignant Phenotype in Tumorigenic Cells

Cells, 8 May 2020